Skip to content

Insmed INSM Current Debt

Current Debt at other companies

Sarepta Therapeutics, Inc. logo
Sarepta Therapeutics, Inc.SRPT
$0-100%
ANI Pharmaceuticals logo
ANI PharmaceuticalsANIP
$19.3M+72.4%
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
$720M
Savara logo
SavaraSVRA
$0

Other financials

Income statement

See full
Revenue$306.0M+230%
Gross profit$258.5M+261%
Operating income-$153.3M+38.2%
Net income-$163.6M+36.3%
EPS (diluted)-$0.76+46.5%

Balance sheet

See full
Cash & equivalents$582.2M+44.4%
Total debt$580.3M-49.2%
Total equity$704.9M+611%
Total assets$2.1B+15.2%

Cash flow

See full
Operating cash flow-$222.7M+15.0%
CapEx$3.5M-65.4%
Free cash flow-$226.2M+16.9%

Valuation

See full
Market cap$22.57B+13.2%
Enterprise value$22.57B+17.3%
P/S27.5×-22.6×

Profitability

See full
Gross margin81.8%+5.3pp
Operating margin-140.6%-43.9pp
Net margin-144.4%-45.3pp
FCF margin-112.5%-35.3pp

Returns & leverage

See full
Return on equity-294.5%
Debt / equity0.8×-10.7×
Current ratio4.5×-1.4×

Where this comes from

Reported directly by Insmed in its filing.

Tagged under the XBRL concept us-gaap:FinanceLeaseLiabilityCurrent.

The official record: Insmed’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Insmed's current debt.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Insmed's current debt?
Insmed (INSM) reported current debt of $3.45M in Q1 2026.
How has Insmed's current debt changed year-over-year?
Insmed's current debt increased by 12.8% year-over-year, from $3.05M to $3.45M.
What is the long-term trend for Insmed's current debt?
Over 5 years (2020 to 2025), Insmed's current debt has grown at a 25.3% compound annual growth rate (CAGR), from $1.08M to $3.35M.
What does current debt mean?
The portion of long-term debt maturing within the next 12 months, requiring refinancing or repayment from operating cash flows.